Pegylated agents

DrugDrug NameDrug Indication
DB05202Egaptivon pegolPlatelet aggregation, thrombosis and acute coronary syndromes
DB12578Lexaptepid PegolNot Available
DB08894PeginesatidePeginesatide is used for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis
DB13200LipegfilgrastimIndicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) [L2441].
DB12258Abicipar PegolNot Available
DB14712ElapegademaseElapegademase is approved for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.[L4654] This condition was previously treated by the use of pegamedase bovine as part of an enzyme replacement therapy.[L4655] ADA-SCID is a genetically inherited disorder that is very rare and characterized by a deficiency in the adenosine deaminase enzyme. The patients suffering from this disease often present a compromised immune system. This condition is characterized by very low levels of white blood cells and immunoglobulin levels which results in severe and recurring infections.[L4656]
DB05321PEG-uricaseInvestigated for use/treatment in hyperuricemia.
DB09329Antihemophilic Factor (Recombinant), PEGylatedFor the management of hemophilia A (congenital factor VIII deficiency) [FDA label], [A32064]. This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older) with hemophilia A (congenital factor VIII deficiency). It is also used for on-demand treatment and control of bleeding and routine prophylaxis of bleeding episodes. It is not indicated for the treatment of von Willebrand disease [FDA label].
DB11661Eptacog alfa pegol (activated)Not Available
DB00061PegademaseFor treatment of adenosine deaminase deficiency
DB12842PegamotecanNot Available
DB09122Peginterferon beta-1aFor the treatment of patients with relapsing forms of multiple sclerosis.
DB06022GlycoPEG-GCSFInvestigated for use/treatment in adverse effects (chemotherapy) and neutropenics.
DB04895PegaptanibFor the treatment of neovascular (wet) age-related macular degeneration.
DB09208PegloticaseFor the treatment of chronic gout in adult patients refractory to conventional therapy.
DB08904Certolizumab pegolCertolizumab pegol has been approved for several different conditions listed below: - Symptomatic management of Chron's disease patients and for the maintenance of clinical response in patients with moderate to severe disease with inadequate response to conventional therapy. - Treatment of adult patients with moderate to severely active rheumatoid arthritis. - Treatment of adult patients with active psoriatic arthritis. - Treatment of adult patients with active ankylosing spondylitis. - Treatment of adult patients with moderate-to-severe plaque psoriasis that are candidates for systemic therapy or phototherapy.[FDA label] - Treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation.[L5819] In Canada, certolizumab pegol is additionally approved in combination with [methotrexate] for the symptomatic treatment, including major clinical response, and for the reduction of joint damage in adult patients with moderately to severely active rheumatoid arthritis and psoriatic arthritis.[L5825] Inflammation is a biological response against a potential threat. This response can be normal but in certain conditions, the immune system can attack the body's normal cells or tissues which causes an abnormal inflammation.[L5840] TNF-alpha has been identified as a key regulator of the inflammatory response. The signaling cascades of this inflammatory mediator can produce a wide range of reactions including cell death, survival, differentiation, proliferation and migration.[A176660]
DB06293PegnivacoginInvestigated for use/treatment in thrombosis, coronary artery disease, and vascular diseases.
DB11707Olaptesed PegolNot Available
DB06325PegpleranibInvestigated for use/treatment in macular degeneration and eye disorders/infections.
DB03394Heptaethylene glycolNot Available
DB11225Peg-100 stearateNot Available
DB06611PegsunerceptInvestigated for use/treatment in rheumatoid arthritis.
DB14700Damoctocog alfa pegolIndicated for use in previously treated adults and adolescents (12 years of age and above) with hemophilia A (congenital Factor VIII deficiency) for: On-demand treatment and control of bleeding episodes [FDA label], perioperative management of bleeding [FDA label], and routine prophylaxis to reduce the frequency of bleeding episodes [FDA label].
DB11567Insulin peglisproNot Available
DB12839PegvaliasePegvaliase is indicated for the management of phenylketonuria (PKU) in adult patients who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management.
DB14142Methoxy PEG-12 retinamideNot Available
DB09107Methoxy polyethylene glycol-epoetin betaFor the treatment of patients with anaemia associated with chronic kidney disease. Not a substitute for RBC transfusion if immediate correction of anemia is required.
DB12814Cepeginterferon alfa-2BNot Available
DB13933Nonacog beta pegolNonacog beta pegol is indicated for the use in adults and children with hemophilia B for control and prevention of bleeding episodes, routine prophylaxis and perioperative management.[L1100] In the EMA approval, it is also indicated for on-demand treatment of bleeding episodes.[L1099] Hemophilia B is characterized by a deficiency in the coagulation factor IX which results in prolonged oozing after injuries and delayed or recurring bleeding prior wound healing. Hemophilia B patients present more frequent bleeding episodes during childhood and adolescence than in adulthood.[T56]
DB00059PegaspargaseFor treatment of acute lymphoblastic leukemia
DB06811PolidocanolPolidocanol is a sclerosing agent indicated to treat uncomplicated spider veins and uncomplicated reticular veins in the lower extremity.
DB00008Peginterferon alfa-2aPeginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies. Peginterferon alfa-2a is also indicated as a monotherapy for adult patients with HBeAg positive and HBeAg negative chronic hepatitis B infection who have compensated liver disease and evidence of viral replication and liver inflammation [FDA Label].
DB05860Peginterferon alfacon-1Investigated for use/treatment in hepatitis (viral, C).
DB00022Peginterferon alfa-2bPeginterferon alfa-2b is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
DB01839Propylene glycolNot Available
DB09287Polyethylene glycolUsed to treat and prevent constipation.
DB11077Polyethylene glycol 400PEG-400 has been indicated for the temporary relief of burning and irritation due to dryness of the eye, and for protection against further irritation and desiccation [L1795], [L1796], [L1797].
DB00082PegvisomantPegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly.
DB00019PegfilgrastimPegfilgrastim is indicated for use in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies to reduce the incidence of infection. It is also indicated to increase in patients with acute myelosuppresive radiation exposure.
DrugDrug NameTargetType
DB05202Egaptivon pegolvon Willebrand factortarget
DB05202Egaptivon pegolPlatelet glycoprotein Ib alpha chaintarget
DB08894PeginesatideErythropoietin receptortarget
DB13200LipegfilgrastimGranulocyte colony-stimulating factor receptortarget
DB05321PEG-uricaseUric acid degradation bifunctional proteintarget
DB09329Antihemophilic Factor (Recombinant), PEGylatedvon Willebrand factortarget
DB09329Antihemophilic Factor (Recombinant), PEGylatedvon Willebrand factorcarrier
DB00061PegademaseGrowth factor receptor-bound protein 2target
DB09208PegloticaseUric acidtarget
DB08904Certolizumab pegolTumor necrosis factortarget
DB08904Certolizumab pegolAlcohol dehydrogenase [NADP(+)]enzyme
DB06325PegpleranibPlatelet-derived growth factor subunit Btarget
DB03394Heptaethylene glycolCarbonyl reductase [NADPH] 1target
DB03394Heptaethylene glycolCarbonyl reductase [NADPH] 1enzyme
DB14700Damoctocog alfa pegolCoagulation factor VIIItarget
DB09107Methoxy polyethylene glycol-epoetin betaErythropoietin receptortarget
DB13933Nonacog beta pegolCoagulation factor VIItarget
DB13933Nonacog beta pegolCoagulation factor VIIItarget
DB13933Nonacog beta pegolCoagulation factor Xtarget
DB00059PegaspargaseThyroxine-binding globulincarrier
DB00008Peginterferon alfa-2aInterferon alpha/beta receptor 2target
DB00008Peginterferon alfa-2aInterferon alpha/beta receptor 1target
DB00008Peginterferon alfa-2aCytochrome P450 1A2enzyme
DB00022Peginterferon alfa-2bInterferon alpha/beta receptor 1target
DB00022Peginterferon alfa-2bInterferon alpha/beta receptor 2target
DB00022Peginterferon alfa-2bCytochrome P450 1A2enzyme
DB00022Peginterferon alfa-2bCytochrome P450 2D6enzyme
DB00022Peginterferon alfa-2bCytochrome P450 2C9enzyme
DB01839Propylene glycolCoagulation factor XIII A chaintarget
DB01839Propylene glycolHaloalkane dehalogenasetarget
DB01839Propylene glycolClavaminate synthase 1target
DB01839Propylene glycolLactaldehyde reductasetarget
DB01839Propylene glycolB12-independent glycerol dehydratasetarget
DB11077Polyethylene glycol 400Oxidoreductase HTATIP2target
DB11077Polyethylene glycol 400Cytochrome P450 4A11enzyme
DB11077Polyethylene glycol 400Alcohol dehydrogenase class-3enzyme
DB11077Polyethylene glycol 400Sulfotransferase 1A1enzyme
DB11077Polyethylene glycol 400Ectonucleotide pyrophosphatase/phosphodiesterase family member 1target
DB00082PegvisomantGrowth hormone receptortarget
DB00082PegvisomantSterol 26-hydroxylase, mitochondrialenzyme
DB00082PegvisomantGlutamine synthetaseenzyme
DB00082PegvisomantCytochrome P450 2C18enzyme
DB00082PegvisomantCytochrome P450 3A4enzyme
DB00082PegvisomantCytochrome P450 2C19enzyme
DB00082PegvisomantCytochrome P450 4A11enzyme
DB00019PegfilgrastimGranulocyte colony-stimulating factor receptortarget
DB00019PegfilgrastimNeutrophil elastasetarget